Abstract
1 Plasma drug concentrations and attenuations in sub-maximal exercise tachycardia were measured in six healthy subjects 24 h after the third and fourth doses of Inderal LA® and 16/260 oxprenolol Oros administered once daily.
2 Both drugs significantly reduced exercise heart rates relative to the placebo response, at both observation times. The mean percentage reductions on the third and fourth days were, respectively, 15.7 and 11.6% for Inderal LA compared with 18.1 and 12.2% for 16/260 oxprenolol Oros. The differences between formulations were not statistically significant.
3 The mean plasma concentrations at 24 h on the third and fourth day were 119 and 101 ng/g for oxprenolol and 16.2 and 15.8 ng/g for propranolol.
Keywords: propranolol, oxprenolol, Oros formulation, plasma concentration, β-adrenoceptor blockade
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Degen P. H., Riess W. Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr. 1976 Jun 9;121(1):72–75. doi: 10.1016/s0021-9673(00)82299-2. [DOI] [PubMed] [Google Scholar]
- Leahey W. J., Neill J. D., Varma M. P., Shanks R. G. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol. 1980 Jun;17(6):419–424. doi: 10.1007/BF00570158. [DOI] [PubMed] [Google Scholar]
- McAinsh J., Baber N. S., Smith R., Young J. Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol. 1978 Aug;6(2):115–121. doi: 10.1111/j.1365-2125.1978.tb00835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petrie J. C., Jeffers T. A., Robb O. J., Scott A. K., Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. Br Med J. 1980 Jun 28;280(6231):1573–1574. doi: 10.1136/bmj.280.6231.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Serlin M. J., Orme M. L., MacIver M., Green G. J., Sibeon R. G., Breckenridge A. M. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol. 1983 May;15(5):519–527. doi: 10.1111/j.1365-2125.1983.tb02085.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Theeuwes F., Swanson D. R., Guittard G., Ayer A., Khanna S. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol. 1985;19 (Suppl 2):69S–76S. doi: 10.1111/j.1365-2125.1985.tb02745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Woods K. L., Jack D. B., Kendall M. J., Halsey A., O'Donnell M. L., Warrington S. J., John V. A. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers. Br J Clin Pharmacol. 1985;19 (Suppl 2):177S–184S. doi: 10.1111/j.1365-2125.1985.tb02759.x. [DOI] [PMC free article] [PubMed] [Google Scholar]